DXC Technology Reports Steep Earnings Decline, $655M Tax Litigation Exposure, and Goodwill Impairment
Summary
DXC Technology reported a sharp decline in net income and EPS for fiscal 2026, alongside a significant $655 million tax litigation exposure and goodwill impairment, despite a slight increase in free cash flow and debt reduction.
Key Events
-
Steep Earnings Decline
Net income plummeted to $18 million from $389 million, and diluted EPS fell to $0.10 from $2.10 year-over-year for fiscal 2026.
-
Organic Revenue Contraction
Full fiscal year 2026 organic revenue decreased by 4.8%, with a book-to-bill ratio of 0.98x indicating slowing new business acquisition relative to revenue.
-
Significant Tax Litigation Exposure
The company faces a total cash tax exposure of approximately $655 million from three U.S. Tax Court issues. The IRS was granted summary judgment on a $125 million foreign currency loss issue, leading to an increased accrual.
-
Goodwill Impairment
A $14 million goodwill impairment loss was recognized in the Global Infrastructure Services (GIS) segment during the first quarter of fiscal 2026, following a segment structure change.
Analysis
DXC Technology's annual report reveals a challenging fiscal year 2026, marked by a dramatic drop in net income and diluted EPS, coupled with a significant tax litigation exposure. The company's organic revenue continued to decline, and a goodwill impairment was recognized. While the company managed to increase free cash flow and reduce overall debt, these positive capital management efforts are overshadowed by the core business performance and substantial legal and financial risks. The pending tax court decisions represent a material financial overhang, and the sustained organic revenue decline indicates ongoing operational challenges. Investors should closely monitor the outcomes of the tax litigation and the company's ability to reverse revenue trends.
At the time of this filing, DXC was trading at $10.01 on NYSE in the Technology sector, with a market capitalization of approximately $2B. The 52-week trading range was $11.07 to $17.26. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.